查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1378788

2023-2028 年青光眼治疗市场报告（依药物类别、适应症、最终使用者和地区）

Glaucoma Therapeutics Market Report by Drug Class, Indication, End User, and Region 2023-2028
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

抽象的

2022年，全球青光眼治疗市场规模达到74亿美元。展望未来， IMARC Group预计到2028年市场规模将达到108亿美元，2022-2028年复合年增长率（CAGR）为6.5%。青光眼在全球范围内的盛行率不断上升、早期检测诊断技术的不断进步、眼科远距医疗的日益普及以及外科手术中的众多技术创新是推动市场发展的一些因素。

青光眼是一组导致视神经损伤的眼部疾病，可导致视力丧失。这些干预措施通常透过药物、雷射治疗或手术进行管理，旨在降低眼内压（IOP），眼内压是青光眼进展的关键因素。青光眼治疗通常包括前列腺素、β受体阻断剂和α受体激动剂等药物，通常以眼药水形式给药，目标是减少眼液产生或改善其流出。雷射治疗（例如小梁成形术）是另一种方法，其中雷射光束聚焦在眼睛的引流系统上以促进液体排出。小梁切除术和引流植入手术等外科手术是创造液体引流替代通道的最终手段。这些疗法可以单独使用，也可以组合使用，这取决于青光眼的严重程度和类型。

全球市场主要是由全球青光眼盛行率不断上升所推动的，特别是在老年族群。与此一致的是，早期检测诊断技术的不断进步正在为市场提供动力。此外，新药物输送方法的开发是重要的生长诱导因素。除此之外，製药公司加大研发投资正在为市场创造新的途径。除此之外，人们越来越意识到定期眼科检查和及时治疗青光眼症状的重要性，这鼓励了这些疗法的采用。此外，卫生组织传播青光眼知识的措施也对市场产生了正面影响。除此之外，专业眼科护理中心数量的成长正在推动市场。对该市场做出贡献的其他一些因素包括获得医疗保健的中产阶级人口不断扩大、对个人化医疗的日益关注以及创新治疗产品的推出。

青光眼治疗市场趋势/驱动因素：

手术过程中的众多技术创新

外科手术技术创新的出现对全球市场产生了重大影响。最具突破性的进展之一是微创青光眼手术（MIGS）。事实证明，这些手术干预措施具有变革性，因为与小梁切除术等传统手术方法相比，併发症更少，恢復时间更短，并且更容易实施。 MIGS 的简单性为外科医生提供了更多选择来有效管理疾病，同时最大限度地减少患者的潜在风险和不适。此外，微型支架和新型引流系统等外科医疗器材的进步进一步提高了青光眼手术的效果。这些进步反过来又增加了全球医疗保健从业者和患者对手术解决方案作为青光眼可行治疗选择的信任。

眼科远距医疗的采用率不断上升

远距医疗已日益成为医疗保健不可或缺的一部分，当涉及青光眼治疗市场时，其在眼科的应用尤其值得关注。医疗数位化，加上软硬体技术的进步，使得远距会诊变得实用且有效。现在患者可以监测自己的病情，而无需频繁去医院，这对于居住在农村或偏远地区的患者尤其有利。医疗保健服务范围的扩大提高了患者的参与度，从而有助于取得更好的结果。远距会诊可以实现持续监控，即时资料可以提醒医疗保健提供者註意患者病情的变化，可能需要立即干预。增强的资料收集能力也为研究提供了前所未有的机会，从而有可能加速新治疗方式的发展。

更重视病人照护的整体方法

综合的整体治疗计划通常涉及多学科的医疗保健提供者团队，包括营养师、物理治疗师和心理咨商师等。这不仅为患者提供了更全面的治疗计划，而且还开启了医疗保健生态系统内的交叉销售和追加销售机会。重点已经从治疗症状转向更全面的方法，同时考虑患者教育、生活方式的改变和预防措施以及医疗干预措施。整体方法也认识到饮食、运动和压力管理等生活方式因素在治疗青光眼中的作用。对患者进行有关有助于降低眼内压的食物类型和活动的教育，眼内压是青光眼的关键因素。这种多管齐下的方法不仅提高了医疗效果，而且改善了患者的整体生活品质。

青光眼治疗行业细分：

IMARC Group提供了全球青光眼治疗市场报告各细分市场主要趋势的分析，以及 2023-2028 年全球、区域和国家层面的预测。我们的报告根据药物类别、适应症和最终用户对市场进行了分类。

按药物类别细分：

前列腺素类似物

β受体阻断剂

α肾上腺素激动剂

碳酸酐酶抑制剂

复方药物

其他的

前列腺素类似物代表最大的细分市场

该报告根据药物类别提供了详细的市场细分和分析。这包括前列腺素类似物、β受体阻断剂、α肾上腺素激动剂、碳酸酐酶抑制剂、组合药物等。根据该报告，前列腺素类似物代表了最大的部分。

前列腺素类似物市场的主要驱动力是其降低眼压的功效，与其他类别的青光眼药物相比，其全身副作用较少。这些药物每日一次给药的便利性也有助于提高患者的依从性，从而增加其市场需求。配方和输送机制的创新是其市场份额的另一个主要因素。然而，智慧财产权到期和随后仿製药的进入对市场成长构成了挑战。最后，它们与其他类别的青光眼药物的多功能兼容性使它们成为联合疗法的首选，从而增强了该领域的突出地位。

另一方面，β受体阻断剂、α肾上腺素激动剂、碳酸酐酶抑制剂、组合药物和其他细分市场受到多种因素的影响，例如可负担性、不同的作用机制和完善的安全性。这些药物通常在前列腺素类似物禁忌或无效的情况下使用。儘管它们有效，但每日多次给药的需要可能会影响患者的依从性。此类仿製药的可用性也使其成为具有成本效益的治疗选择。

按指示细分：

开角型青光眼

闭角型青光眼

其他的

开角型青光眼代表最大的细分市场

该报告根据该指标提供了详细的市场细分和分析。这包括开角型青光眼、闭角型青光眼等。根据该报告，开角型青光眼占最大部分。

开角型青光眼的发生率主要是由其盛行率推动的，占全球青光眼病例的大多数。认识的提高和诊断技术的进步使得这种情况的检测更早、更频繁。从药物到手术等多种治疗方案的出现，为治疗开角型青光眼提供了综合方法。人口老化进一步提高了发病率，从而推动了对治疗产品的需求。政府针对眼睛健康的措施有助于该细分市场的整体市场成长。

另一方面，闭角型青光眼和其他疾病的增长主要是由人口老化所驱动的，因为这种情况在老年人中更为普遍。诊断技术的进步也有助于更早、更准确地检测病情，从而促进了该领域的扩张。此外，人们对未经治疗的闭角型青光眼（可能导致失明）严重性的认识不断提高，导致对有效治疗的需求更高。

按最终用户划分：

医院

眼科诊所

门诊手术中心

其他的

医院占大部分市场份额

该报告提供了基于最终用户的详细市场细分和分析。这包括医院、眼科诊所、门诊手术中心等。报告称，医院占最大部分。

医院是青光眼治疗市场的主要消费者，因为它们有能力提供先进的诊断和手术介入。医疗保健设施的整合和对最先进眼科部门的投资促进了该领域的成长。此外，医院通常是紧急眼科疾病的第一个接触点，因此将它们定位为重要的利害关係人。公共和私人保险范围也鼓励在医院环境中进行治疗，增加患者吞吐量和青光眼药物的消耗量。

另一方面，眼科诊所、门诊手术中心和其他细分市场的成长可归因于对眼科护理的专门关注、先进诊断设备的可用性以及更快的患者周转率。消费者对专业照护的偏好不断增加也是一个因素。医疗保健服务的分散化和门诊手术中心的扩张使得这些设施可以进行小手术和定期检查。灵活的支付方式和更短的等待时间进一步支持了成长。

按地区划分：

北美洲

美国

加拿大

亚太地区

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美表现出明显的主导地位，占据最大的青光眼治疗市场份额

市场研究报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美占据最大的市场份额。

北美地区的市场受到高额医疗保健支出、稳健的保险框架以及领先製药公司的存在的显着推动。此外，该地区人口多样化且老化，从而产生了对青光眼治疗的自然需求。在研发方面的大量投资的支持下，药物配方和输送方面的技术进步也推动了市场的成长。

加速审批和拨款方面的监管支援可促进创新，为市场扩张提供有利的环境。政府在医疗保健教育和眼科筛检方面的措施有助于早期诊断，进而推动对治疗的需求。专业眼科诊所和门诊手术中心的便利性又增加了一层便利，鼓励及时介入。

品牌药和仿製药的供应提供了不同价位的选择，迎合了广泛的消费者群体。此外，公共和私营部门在医疗保健措施方面的合作有助于提高意识并促进新型治疗解决方案进入和接受市场。

竞争格局：

市场上的主要参与者一直致力于开发更有效、更侵入性的治疗方案。他们正在大量投资于临床试验，以生产能够提供更持久缓解且副作用更少的药物和设备。与研究机构和医疗保健组织的合作是这些关键参与者的常见策略。市场领导者也透过推出专门设计用于治疗不同类型青光眼的创新产品来扩大其产品组合。此外，这些公司正在努力满足严格的监管要求，确保其产品安全有效。此外，他们还注重患者教育和意识计划，作为其市场扩张策略的一部分。

该报告对市场竞争格局进行了全面分析。也提供了所有主要公司的详细资料。市场上的一些主要参与者包括：

艾利药厂

艾尔建公司

博士伦公司（博士伦健康公司）

艾诺泰克製药公司

默克公司

诺华公司

辉瑞公司

参天製药股份有限公司

SIFI公司

梯瓦製药工业股份有限公司

最近的发展：

2022 年 11 月，Aerie Pharmaceuticals, Inc. 被全球眼科护理领导者爱尔康收购。透过此交易，爱尔康新增了商业产品Rocklatan（奈达舒地尔和拉坦前列素眼药水）0.02%/0.005%和Rhopressa（奈达舒地尔眼药水）0.02%、AR-15512 ，这是一种治疗干眼症的3期候选产品，也是一条管道眼科药品候选者。

2023 年7 月，Bausch Health Companies Inc. 宣布，Bausch Health 的全资子公司、安大略省有限合伙企业Bausch Receivables Funding LP 已与KKR 及其信贷基金和帐户签订了6 亿美元的无追索权融资协议。该贷款将以 Bausch Health 全资子公司产生的某些应收帐款作为抵押。

默克宣布，欧盟委员会 (EC) 已批准默克的抗 PD-1 疗法 KEYTRUDA 与曲妥珠单抗、氟嘧啶和含铂化疗联合用于局部晚期不可切除或转移性人类的一线治疗肿瘤表达PD-L1 的成人表皮生长因子受体2 (HER2) 阳性胃或胃食道交界处(GEJ) 腺癌（综合阳性评分[CPS] ≥1）。

本报告回答的关键问题

  • 全球青光眼治疗市场有多大
  • 2023-2028年全球青光眼治疗市场的预期成长率是多少
  • 推动全球青光眼治疗市场的关键因素是什么
  • COVID-19 对全球青光眼治疗市场有何影响
  • 根据药物类别，全球青光眼治疗市场的细分如何
  • 根据适应症，全球青光眼治疗市场的细分如何
  • 基于最终用户的全球青光眼治疗市场的细分是什么
  • 全球青光眼治疗市场的关键区域有哪些
  • 谁是全球青光眼治疗市场的主要参与者/公司

本报告回答的关键问题

  • 全球青光眼治疗市场有多大？
  • 2023-2028年全球青光眼治疗市场的预期成长率是多少？
  • 推动全球青光眼治疗市场的关键因素是什么？
  • COVID-19 对全球青光眼治疗市场有何影响？
  • 根据药物类别，全球青光眼治疗市场的细分如何？
  • 根据适应症，全球青光眼治疗市场的细分如何？
  • 基于最终用户的全球青光眼治疗市场的细分情况如何？
  • 全球青光眼治疗市场的关键区域有哪些？
  • 谁是全球青光眼治疗市场的主要参与者/公司？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球青光眼治疗市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：按药物类别分類的市场细分

  • 前列腺素类似物
    • 市场走向
    • 市场预测
  • β受体阻断剂
    • 市场走向
    • 市场预测
  • α肾上腺素激动剂
    • 市场走向
    • 市场预测
  • 碳酸酐酶抑制剂
    • 市场走向
    • 市场预测
  • 复方药物
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：按迹象分類的市场

  • 开角型青光眼
    • 市场走向
    • 市场预测
  • 闭角型青光眼
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：最终用户的市场区隔

  • 医院
    • 市场走向
    • 市场预测
  • 眼科诊所
    • 市场走向
    • 市场预测
  • 门诊手术中心
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：按地区分類的市场区隔

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太地区
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 按国家/地区分類的市场细分
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Aerie Pharmaceuticals Inc.
    • Allergan Plc
    • Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
    • Inotek Pharmaceuticals Corp.
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Santen Pharmaceutical Co. Ltd.
    • SIFI SpA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112023A2770

Abstract

The global glaucoma therapeutics market size reached US$ 7.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 10.8 Billion by 2028, exhibiting a growth rate (CAGR) of 6.5% during 2022-2028. The growing prevalence of glaucoma across the globe, continual advancements in diagnostic technologies for early detection, the rising adoption of telemedicine in ophthalmology, and numerous technological innovations in surgical procedures represent some of the factors that are propelling the market.

Glaucoma is a group of eye conditions resulting in optic nerve damage, which can lead to vision loss. Typically managed through medications, laser treatment, or surgery, these interventions aim to reduce intraocular pressure (IOP), which is a key factor in glaucoma progression. Glaucoma therapeutics typically include medications such as prostaglandins, beta-blockers, and alpha agonists are commonly administered in eye drop form, targeting the reduction of eye fluid production or its improved outflow. Laser treatment, such as trabeculoplasty, is another method where laser beams focus on the eye's drainage system to facilitate fluid exit. Surgical procedures like trabeculectomy and drainage implant surgery are the final resorts to create alternative channels for fluid drainage. These therapeutics are used either in isolation or in combinations depending on the severity and type of glaucoma.

The global market is primarily driven by the growing prevalence of glaucoma across the globe, particularly among the geriatric population. In line with this, continual advancements in diagnostic technologies for early detection are providing an impetus to the market. Moreover, the development of new drug delivery methods is acting as a significant growth-inducing factor. In addition to this, increased investment in research and development by pharmaceutical companies is creating new avenues in the market. Besides this, the rising awareness about the importance of regular eye check-ups and timely treatment of glaucoma symptoms is encouraging the adoption of these therapeutics. Also, initiatives by health organizations to disseminate knowledge about glaucoma are positively impacting the market. Apart from this, growth in the number of specialized eye care centers is propelling the market. Some of the other factors contributing to the market include an expanding middle-class population with access to healthcare, a growing focus on personalized medicine, and the introduction of innovative therapeutic products.

Glaucoma Therapeutics Market Trends/Drivers:

Numerous technological innovation in surgical procedures

The advent of technological innovation in surgical procedures has significantly influenced the global market. One of the most groundbreaking developments is Minimally Invasive Glaucoma Surgeries (MIGS). These surgical interventions have proved to be transformative by causing fewer complications, necessitating shorter recovery periods, and being easier to perform than traditional surgical methods like trabeculectomy. The ease of MIGS has empowered surgeons with more options to manage the disease effectively while minimizing the potential risks and discomfort to the patient. In addition, advancements in surgical medical devices such as micro-stents and new drainage systems have further improved the effectiveness of glaucoma surgeries. These advancements have, in turn, increased the trust among healthcare practitioners and patients across the globe in surgical solutions as viable treatment options for glaucoma.

Rising adoption of telemedicine in ophthalmology

Telemedicine has increasingly become an integral part of healthcare, and its applications in ophthalmology are particularly noteworthy when it comes to the glaucoma therapeutics market. The digitalization of healthcare, coupled with technological advancements in software and hardware, has made remote consultations both practical and effective. Patients can now have their conditions monitored without the need for frequent hospital visits, which is especially beneficial for those residing in rural or remote locations. This wider reach of healthcare services enhances patient engagement, thereby contributing to better outcomes. Remote consultations enable continuous monitoring, and real-time data can alert healthcare providers to changes in a patient's condition that may require immediate intervention. The enhanced data collection capabilities also offer unprecedented opportunities for research, thereby potentially accelerating the development of new treatment modalities.

An enhanced focus on holistic approaches to patient care

An integrated, holistic treatment plan often involves a multi-disciplinary team of healthcare providers, including nutritionists, physiotherapists, and psychological counselors, among others. This not only gives patients a more comprehensive treatment plan but also opens up cross-selling and up-selling opportunities within the healthcare ecosystem. The focus has moved beyond treating the symptoms to a more integrated approach, taking into account patient education, lifestyle changes, and preventive measures alongside medical interventions. A holistic approach also recognizes the role of lifestyle factors such as diet, exercise, and stress management in managing glaucoma. Patients are educated about the types of foods and activities that can help in reducing intraocular pressure, which is a critical factor in glaucoma. This multi-pronged approach not only enhances the effectiveness of medical treatments but also improves the overall quality of life for the patients.

Glaucoma Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global glaucoma therapeutics market report, along with forecasts at the global, regional, and country levels for 2023-2028. Our report has categorized the market based on drug class, indication and end user.

Breakup by Drug Class:

Prostaglandin Analogs

Beta Blockers

Alpha Adrenergic Agonists

Carbonic Anhydrase Inhibitors

Combination Drugs

Others

Prostaglandin analogs represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes prostaglandin analogs, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs and others. According to the report, prostaglandin analogs represented the largest segment.

The prostaglandin analogs segment in the market is predominantly driven by their efficacy in reducing intraocular pressure with fewer systemic side effects compared to other classes of glaucoma medications. The once-daily dosing convenience of these drugs also contributes to patient compliance, thereby increasing its market demand. Innovation in formulations and delivery mechanisms is another major factor contributing to its market share. Intellectual property expiry and subsequent entry of generics, however, pose a challenge to market growth. Lastly, their versatile compatibility with other classes of glaucoma medications makes them a preferred choice in combination therapies, bolstering the segment's prominence.

On the other hand, the beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs and other segments are influenced by a diverse range of factors such as affordability, varied mechanisms of action, and well-established safety profiles. These drugs are often prescribed in cases where Prostaglandin Analogs are contraindicated or not effective. Despite their efficacy, the need for multiple daily dosing can impact patient compliance. Availability of generics in this category also makes it a cost-effective option for treatment.

Breakup by Indication:

Open Angle Glaucoma

Angle Closure Glaucoma

Others

Open angle glaucoma represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the indication. This includes open angle glaucoma, angle closure glaucoma and others. According to the report, open angle glaucoma represented the largest segment.

The open-angle glaucoma segment is primarily fueled by its prevalence, constituting the majority of glaucoma cases globally. Increased awareness and advancements in diagnostic techniques have led to earlier and more frequent detection of this condition. The availability of multiple treatment options, ranging from medications to surgeries, offers a comprehensive approach to managing open-angle glaucoma. Aging demographics further amplify the incidence rates, thereby driving demand for therapeutic products. Government initiatives aimed at eye health contribute to the overall market growth for this segment.

On the other hand, the growth in angle closure glaucoma and other segments is primarily driven by an aging population, as the condition is more prevalent among older adults. Advances in diagnostic technologies have also contributed to the segment's expansion by enabling earlier and more accurate detection of the condition. In addition, the increased awareness about the severity of untreated angle-closure glaucoma, which can lead to blindness, has led to higher demand for effective treatments.

Breakup by End User:

Hospitals

Ophthalmic Clinics

Ambulatory Surgery Centers

Others

Hospitals accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, ophthalmic clinics, ambulatory surgery centers and others. According to the report, hospitals represented the largest segment.

Hospitals are major consumers in the glaucoma therapeutics market, given their capability to offer advanced diagnostic and surgical interventions. The consolidation of healthcare facilities and investment in state-of-the-art ophthalmic departments contribute to the segment's growth. Additionally, hospitals are often the first point of contact for emergency eye conditions, thereby positioning them as crucial stakeholders. Public and private insurance coverages also incentivize treatment in hospital settings, increasing patient throughput and consumption of glaucoma medications.

On the other hand, the growth in ophthalmic clinics, ambulatory surgery centers, and other segments can be attributed to the specialized focus on eye care, the availability of advanced diagnostic equipment, and faster patient turnover. Increasing consumer preference for specialized care is also a contributing factor. Decentralization of healthcare services and the expansion of ambulatory surgery centers make these settings accessible for minor procedures and regular check-ups. The growth is further supported by flexible payment options and shorter waiting times.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest glaucoma therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The market in the North America region is significantly impelled by high healthcare expenditure, robust insurance frameworks, and the presence of leading pharmaceutical companies are primary drivers. Furthermore, the region is home to a diverse and aging population, thereby creating a natural demand for glaucoma treatments. Technological advancements in drug formulation and delivery, backed by substantial investments in research and development, also fuel market growth.

Regulatory support in terms of expedited approvals and grants fosters innovation, providing a favorable environment for market expansion. Government initiatives in healthcare education and eye screenings contribute to early diagnosis and, in turn, drive demand for therapeutics. Accessibility to specialty ophthalmic clinics and ambulatory surgery centers adds another layer of convenience, encouraging timely intervention.

The availability of both branded and generic drugs offers options across various price points, catering to a wide consumer base. Furthermore, collaborations between public and private sectors in healthcare initiatives serve to increase awareness as well as facilitate entry and acceptance of novel therapeutic solutions in the market.

Competitive Landscape:

The major players in the market are persistently working to develop more effective and less invasive treatment options. They are investing heavily in clinical trials to produce medicines and devices that provide longer-lasting relief with fewer side effects. Collaborations with research institutions and healthcare organizations are common strategies these key players are adopting. Market leaders are also expanding their portfolios by launching innovative products specifically designed to manage different types of glaucoma. Furthermore, these companies are working diligently to meet stringent regulatory requirements, ensuring that their products are both safe and effective. Furthermore, they are also focusing on patient education and awareness programs as a part of their market expansion strategies.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Aerie Pharmaceuticals Inc.

Allergan Plc

Bausch & Lomb Incorporated (Bausch Health Companies Inc.)

Inotek Pharmaceuticals Corp.

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Santen Pharmaceutical Co. Ltd.

SIFI S.p.A

Teva Pharmaceutical Industries Ltd

Recent Developments:

In November 2022, Aerie Pharmaceuticals, Inc. was acquired by Alcon, the global leader in eye care. Through the transaction, Alcon has added the commercial products Rocklatan(netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa(netarsudil ophthalmic solution) 0.02%, AR-15512, a Phase 3 product candidate for dry eye disease and also a pipeline of ophthalmic pharmaceutical product candidates.

In July 2023, Bausch Health Companies Inc. announced that Bausch Receivables Funding LP, an Ontario limited partnership and wholly-owned subsidiary of Bausch Health, has entered into a $600 million non-recourse financing facility with KKR and its credit funds and accounts. The facility will be collateralized by certain accounts receivables originated by a wholly-owned subsidiary of Bausch Health.

Merck & Co. announced that the European Commission (EC) has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in adults whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1).

Key Questions Answered in This Report

  • 1. How big is the global glaucoma therapeutics market?
  • 2. What is the expected growth rate of the global glaucoma therapeutics market during 2023-2028?
  • 3. What are the key factors driving the global glaucoma therapeutics market?
  • 4. What has been the impact of COVID-19 on the global glaucoma therapeutics market?
  • 5. What is the breakup of the global glaucoma therapeutics market based on the drug class?
  • 6. What is the breakup of the global glaucoma therapeutics market based on the indication?
  • 7. What is the breakup of the global glaucoma therapeutics market based on the end user?
  • 8. What are the key regions in the global glaucoma therapeutics market?
  • 9. Who are the key players/companies in the global glaucoma therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Glaucoma Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Prostaglandin Analogs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Beta Blockers
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alpha Adrenergic Agonists
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Carbonic Anhydrase Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Combination Drugs
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Open Angle Glaucoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Angle Closure Glaucoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ophthalmic Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Aerie Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Allergan Plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Inotek Pharmaceuticals Corp.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Novartis AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Santen Pharmaceutical Co. Ltd.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SIFI S.p.A
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Glaucoma Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Glaucoma Therapeutics Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Glaucoma Therapeutics Market: Breakup by Drug Class (in %), 2022
  • Figure 4: Global: Glaucoma Therapeutics Market: Breakup by Indication (in %), 2022
  • Figure 5: Global: Glaucoma Therapeutics Market: Breakup by End User (in %), 2022
  • Figure 6: Global: Glaucoma Therapeutics Market: Breakup by Region (in %), 2022
  • Figure 7: Global: Glaucoma Therapeutics Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 8: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Glaucoma Therapeutics (Beta Blockers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Glaucoma Therapeutics (Beta Blockers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Glaucoma Therapeutics (Combination Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Glaucoma Therapeutics (Combination Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Glaucoma Therapeutics (Other Drug Classes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Glaucoma Therapeutics (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Glaucoma Therapeutics (Other Indications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Glaucoma Therapeutics (Other Indications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Glaucoma Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Glaucoma Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Glaucoma Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Glaucoma Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: North America: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: North America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: United States: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: United States: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Canada: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Canada: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Asia Pacific: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Asia Pacific: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: China: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: China: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Japan: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Japan: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: India: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: India: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: South Korea: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: South Korea: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Australia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Australia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Indonesia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Indonesia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Europe: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Europe: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Germany: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Germany: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: France: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: France: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: United Kingdom: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: United Kingdom: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Italy: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Italy: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Spain: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Spain: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Russia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Russia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Latin America: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Latin America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Brazil: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Brazil: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Mexico: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Mexico: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Middle East and Africa: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Middle East and Africa: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: Global: Glaucoma Therapeutics Industry: SWOT Analysis
  • Figure 83: Global: Glaucoma Therapeutics Industry: Value Chain Analysis
  • Figure 84: Global: Glaucoma Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Glaucoma Therapeutics Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Glaucoma Therapeutics Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 3: Global: Glaucoma Therapeutics Market Forecast: Breakup by Indication (in Million US$), 2023-2028
  • Table 4: Global: Glaucoma Therapeutics Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Glaucoma Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Glaucoma Therapeutics Market: Competitive Structure
  • Table 7: Global: Glaucoma Therapeutics Market: Key Players